R&D | November 21, 2025
Lilly expands biotech footprint with new Gateway Labs in Philadelphia
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
This is the first drug to receive a recommendation for this preventative indication in the European Union
Subscribe To Our Newsletter & Stay Updated
